Webinar: InMed Pharmaceuticals

Webinar: InMed Pharmaceuticals

InMed Pharmaceuticals — 14 videos in collection

More on this equity

InMed Pharmaceuticals (INM) is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol, and is developing IntegraSyn to produce pharmaceutical-grade cannabinoids. InMed recently announced that it has entered into a definitive agreement to acquire BayMedica, a revenue-stage biotechnology company leveraging synthetic biology and pharmaceutical chemistry to develop an efficient, scalable and proprietary platform to produce high-quality, rare cannabinoids for consumer applications. The combined company will be a market leader in the manufacture of rare cannabinoids.

In this webinar, InMed chief executive officer Eric Adams and BayMedica chief executive officer Dr Shane Johnson discuss the acquisition and their plans for the newly combined company.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free